Post by Gilead Sciences on X
Gilead Sciences@GileadSciences
X#GileadNews: We received a #CHMP positive opinion for our combination regimen in PD-(L)1-positive first-line metastatic triple-negative breast cancer. If approved, patients with PD-(L)1 positive mTNBC will have a new treatment option in Europe. t.co
14 likes5 repliesPosted Jul 24, 2026